Researchers compared intensity-modulated radiation therapy versus conventional radiation therapy by evaluating acute toxicities in the GI and GU systems.
Researchers have identified a potential biomarker in patients with stage IV melanoma being treated with the immunotherapy pembrolizumab.
SBRT for men with prostate cancer results in shorter treatment times, low severe toxicity, and excellent cancer control rates.
Data from the Paris-based Molecular Screening for Cancer Treatment Optimization (MOSCATO) trial demonstrates that establishing molecular portraits improves survival for patients with advanced cancer by tailoring treatment to their genetic makeup. The findings were presented at the Molecular Analysis for Personalised Therapy conference.
One assay test reveals statistically lower levels of PD-L1 expression than the others.
Results show that hypofractionated radiation therapy may be a better treatment option for patients with non-small cell lung cancer.
“It is time to rethink how we treat chronic lymphocytic leukemia."
Important factors to consider when developing a clinical pathway for colorectal cancer.
Michael Kolodziej, MD, argues that clinical pathways as we know them will cease to exist as a result of the rise of immunotherapies for the treatment of cancer.
Richard Schilsky, MD kicked off the Clinical Pathways Congress discussing the relationship between clinical pathways development and emergence of precision medicine.